Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$240 Mln
Revenue (TTM)
$42 Mln
Net Profit (TTM)
$0 Mln
ROE
0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.9
Industry P/E
--
EV/EBITDA
1.3
Div. Yield
0 %
Debt to Equity
0.7
Book Value
$0.5
EPS
$-1.4
Face value
--
Shares outstanding
149,889,902
CFO
$-1,014.95 Mln
EBITDA
$-1,294.81 Mln
Net Profit
$-1,534.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Coherus BioSciences (CHRS)
| 21.8 | 3.6 | 21.8 | 114.6 | -36.8 | -34.7 | -22.6 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Coherus BioSciences (CHRS)
| 2.9 | -58.3 | -58.0 | -50.4 | -8.2 | -3.5 | 99.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Coherus BioSciences (CHRS)
|
1.7 | 239.8 | 42.2 | -170.3 | -412.9 | 479.9 | -- | 3.9 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating... factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California. Address: 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065 Read more
Chairman, President & CEO
Mr. Dennis M. Lanfear
Chairman, President & CEO
Mr. Dennis M. Lanfear
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Coherus BioSciences Inc (CHRS) is $1.73 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Coherus BioSciences Inc (CHRS) has given a return of -36.76% in the last 3 years.
Since, TTM earnings of Coherus BioSciences Inc (CHRS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.00
|
2.80
|
|
2024
|
5.59
|
-1.21
|
|
2023
|
-1.56
|
-1.92
|
|
2022
|
-2.12
|
-4.49
|
|
2021
|
-4.27
|
12.55
|
The 52-week high and low of Coherus BioSciences Inc (CHRS) are Rs 2.62 and Rs 0.71 as of 05-Apr-2026.
Coherus BioSciences Inc (CHRS) has a market capitalisation of $ 240 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Coherus BioSciences Inc (CHRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.